SCHEMBL13629289

SCHEMBL13629289

O=C1Nc2ccccc2CCc2ncccc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
MAPK14 Q16539 2/20 0.49
NPC1 O15118 1/20 0.49
MAPK13 O15264 1/20 0.49
MAPK12 P53778 1/20 0.49
MAPK11 Q15759 1/20 0.49
ALDH1A1 P00352 2/20 0.48
ALOX15 P16050 1/20 0.48
MAPK10 P53779 1/20 0.48
HSD17B10 Q99714 1/20 0.48
PDGFRA P16234 1/20 0.43
FER P16591 1/20 0.43
LTK P29376 1/20 0.43
CDK8 P49336 1/20 0.43
ACVR1 Q04771 1/20 0.43
LRRK2 Q5S007 1/20 0.43
DYRK1B Q9Y463 1/20 0.43
MAPT P10636 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13629274 0.88 CYP1A2 (0.54) CYP1A2SMN1; SMN2MAPK14NPC1MAPK13
SCHEMBL13629292 0.84 CYP1A2 (0.43) CYP1A2SMN1; SMN2MAPK14NPC1ALDH1A1
SCHEMBL15985168 0.80 NPC1 (0.48) SMN1; SMN2MAPK14NPC1MAPK13MAPK12
SCHEMBL2086488 0.80 NPC1 (0.62) CYP1A2SMN1; SMN2MAPK14NPC1MAPK13
SCHEMBL8484211 0.78 CYP1A2 (0.56) CYP1A2SMN1; SMN2NPC1ALDH1A1ALOX15
SCHEMBL6385750 0.76 CES1 (0.59) MAPK14ALDH1A1
SCHEMBL13166551 0.75 CYP1A2 (0.37) CYP1A2SMN1; SMN2MAPK14NPC1ALDH1A1
SCHEMBL13629300 0.75 CYP1A2 (0.43) CYP1A2SMN1; SMN2NPC1ALDH1A1ALOX15
SCHEMBL1864779 0.75 CHRM2 (0.45) MAPK14ALDH1A1CHRM2CHRM1PDPK1
SCHEMBL11985681 0.73 CYP1A2 (0.40) CYP1A2SMN1; SMN2MAPK14NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291941-A1 Tyrosine Kinase Inhibitors MERCK SHARP & DOHME CORP. 2009-11-26 US disclosed
US-20090291941-A1 Tyrosine Kinase Inhibitors MERCK SHARP & DOHME CORP. 2009-11-26 US disclosed
US-20090131423-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-05-21 US disclosed
WO-2007050383-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO disclosed
WO-2007050401-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291941-A1 Tyrosine Kinase Inhibitors ABL1, ERBB2, RET CYP1A2 2949/4885SMN1; SMN2 4077/4885MAPK14 460/4885
US-20090131423-A1 Tyrosine Kinase Inhibitors ABL1, ERBB2, MET CYP1A2 4074/4885SMN1; SMN2 3373/4885MAPK14 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.